Drug Profile
RAF 265
Alternative Names: CHIR-265; RAF265Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Small molecules
- Mechanism of Action Raf kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Solid tumours
Most Recent Events
- 22 Sep 2015 No recent reports on development identified - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease) in USA (PO)
- 22 Sep 2015 No recent reports on development identified - Phase-I/II for Malignant melanoma (Late-stage disease) in Netherlands, USA, Switzerland (PO)
- 30 Nov 2013 Novartis completes a phase I/II trial in Malignant melanoma (Late-stage disease) in USA, Netherlands & Switzerland (NCT00304525)